To compare the response rates and the toxicity of the new antifolate edatrexate (EDX) w ith that of methotrexate (MTX) in a randomized trial in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCC) and to compare the durations of response and survival.
HEMOTHERAPY of metastatic or recurrent squa mous cell cancer of the head and neck (SCC) con tinues to be disappointing. Drugs with documented activ ity include methotrexate (MTX), cisplatin, bleomycin and fluorouracil (5-FU).1 Combination chemotherapy regi-in non-small-cell lung cancer and breast cancer. 6 This activity was borne out in subsequent phase II studies. '7-9 In 1988, the European Organization for Research and Treatment of Cancer (EORTC) Head and Neck Cancer Cooperative Group initiated a randomized phase II trial mens produce higher response rates and more toxicity of EDX versus MTX in patients with SCC. A response rate of 24% (complete responses [CRs] plus partial re-than single-agent treatment, but offer no advantage in terms of survival.10 Until now, MTX has been considered the standard treatment for recurrent disease, as it is easy to administer and has a 20% to 40% response rate with acceptable toxicity.1,2 However, the median duration of response is invariably short, which underlines the need for more efficacious compounds in this disease. .10-Ethyl-10-deaza-aminopterin (edatrexate; EDX) is a new struc tural analog of MTX, which was developed through collaborative research at the Memorial Sloan-Kettering Cancer Center in New York and at the Stanford Research Institute International.4"6 It has more favorable cell mem brane characteristics than MTX, is a better substrate for polyglutamylation, and is a more potent inhibitor of the target enzyme, dihydrofolate reductase. 4, 5 In all preclinical models, EDX appeared to have superior antitumor activity as compared with MTX and a similar pattern of toxicity.4,5 In the phase I study, activity was observed sponses [PRs]) for EDX among the first 44 patients treated has been reported elsewhere.10 Because EDX ap peared to be active in SCC, it was decided to continue the randomized phase II study as a phase III trial to detect a possibly significant difference between EDX and MTX. We now report the results of the completed phase III trial comparing EDX with MTX in patients with head and neck cancer.
PATIENTS AND METHODS

Eligibility Criteria
Patients were eligible for this study if they had measurable or assessable metastatic or recurrent SCC, for which no locoregional treatment was available. Prior chemotherapy for metastatic or recur rent disease was not allowed. However, patients were still eligible if they had received induction chemotherapy with cisplatin and 5-FU or bleomycin before locoregional treatment more than 1 year prior to study entry. Patients had to be less than 75 years of age, a Karnofsky score of > 50, a W BC count more than 4,000/^uL and a platelet count more than 100,000//jL, a serum creatinine concentra tion < 120 jumoJ/L or a creatinine clearance s 60 mL/min, adequate liver function tests, no CNS metastases, no third-space fluids, no acute illness or overt infectious disease, and no prior or concomitant second malignancy. Informed consent was obtained from all patients according to policies followed by individual participating institu tions. Patients were randomized to receive either EDX or MTX.
Chemotherapy and Criteria fo r Evaluation o f Toxicity and Response
EDX was administered every week at a dose of 80 mg/m1 as a rapid intravenous (IV) push injection. MTX was administered at a weekly dose of 40 mg/m2, also as a rapid IV push injection. After 120 patients had been randomized, the starting dose of EDX was reduced to 70 mg/m2 because of serious toxicity, including three treatment-related deaths, Two dose increments of 10% were sched uled for both drugs if there was no toxicity after 2 weeks of treatment. Treatment was delayed until recovery in case of & grade 2 myelosuppression or =s grade 1 mucositis, or an increase in serum creati nine concentration, and was subsequently resumed at reduced dos age. Toxicity was scored weekly and is given as worst grade observed during treatment per patient; response assessment was per formed every 4 weeks. Full blood counts and serum creatinine were measured weekly, other biochemistry measurements were performed every 4 weeks. To be assessable for response, patients had to have received at least four injections of the drug. Criteria for measurable and assessable disease and for the assessment of response were standard World Health Organization/International Union Against Cancer (WHO/UICC) criteria.11 Briefly, a CR was defined as the disappearance of all clinically detectable malignant disease for at least 4 weeks. A PR was defined as a ^ 50% decrease in the sum of the products of all diameters of measured lesions for a minimum of 4 weeks without the appearance of new lesions. Stable disease (SD) was defined as a less than 50% regression or less than 25% increase in the sum of diameters for a minimum of 4 weeks without the appearance of new lesions. Progression was defined as a more than 25% increase in the size of any malignant lesion or the appear ance of any new lesion. CR duration was defined as the time elapsed from the date CR was first documented to the date on which disease progression was first noted. PR duration was defined as the time between the first day of treatment and the date on which subsequent progressive disease was first noted. Standard WHO criteria were used for toxicity assessment,11
Statistical Design
The objectives of the study were to evaluate the response rate of weekly EDX as compared with that of weekly MTX in equitoxic doses in patients with SCC, to compare the duration of response and survival, and to compare the toxicity patterns of EDX and MTX. The trial was started as a randomized phase II study with the intention to continue as a phase III trial if a potential advantage for EDX was observed.
The sample size calculation for the phase II part of the trial was based on a two-stage Gehan's method12 with the aim to include 20 patients in each arm and then add five patients for each response observed in the first stage. This guarantees that the probability of an active treatment (real response rate > 20%) exhibiting no response in the first 20 patients (ie false-negative result) is 0.01 and the probabil ity of an inactive treatment (real response rate < 5 % ) showing four responses (20%) in the first 20 patients is 0.0 1.
It was decided a priori that if the EDX arm fulfilled these criteria, the drug should be considered active enough to continue in a compar ative phase III study against the standard MTX treatment. Case record forms were analyzed by the study coordinator every 4 months. By the end of the phase II part, the response rate in the M TX arm was approximately 15%. To detect an improvement in response rate from 15% in the standard arm to 30% in the experimental arm with a two-sided type I error of 0.05 and a power of 80%, it was estimated that 134 patients should be randomized to each treatment arm .13 Randomization was centralized in the EORTC Data Center in Brussels. During randomization, patients were stratified by institu tion at which treatment took place, by site of origin of the tumor, and by previous treatment (none, surgery and/or radiotherapy, and induction chemotherapy before locoregional treatment). Only pa tients with tumors that originated in the oral cavity, oropharynx, hypopharynx, or larynx were included. Patients with nasopharyngeal tumors or tumors of the maxillary or frontal sinuses were not in cluded, since these tumors tend to have a different behavior.2 Strati fication was performed using the Pocock minimization technique.
Duration of survival curves were estimated using the Kaplan-Meier technique.14 Differences in survival duration were compared using a two-sided log-rank test.15 To adjust for any confounding variables and to assess the relative importance of the potential prog nostic factors, Cox's proportional hazards regression model16 was used. Response rates were compared using the Cox logistic regres sion model. Analyses were based on all eligible patients according to an intent-to-treat policy irrespective of treatment compliance.
RESULTS
Between March 1988 and March 1992, 273 patients from 13 institutions were randomized. Nine patients (six EDX and three MTX) were deemed ineligible for the following reasons: inadequate kidney function (n = 1), second tumor (n = 4), poor physical condition (n = 1), prior chemotherapy (n = 1), and nasopharyngeal tumor (n = 2). Of 264 eligible patients, 85% in the EDX group and 84% in the MTX group had at least one measurable lesion. Pretreatment characteristics of the 264 eligible patients are listed in Table 1 . The treatment arms were well balanced for all evaluated characteristics. Forty-eight percent of the patients had a Karnofsky score of 70 or 80, and 46% of 90 or 100. Ninety-three percent of patients had received prior radiotherapy with either curative (81%) or palliative (12%) intent. Sixty-two percent of patients had locoregional disease only, and 38% had metastatic disease with or without locoregional recurrence. Six per cent were newly diagnosed with distant metastases.
Treatment
Three of 264 eligible patients refused treatment after ran domization and did not receive any chemotherapy. Thirtyseven percent of patients received between one and five weekly injections of either drag, while 62% received six or more. Numbers of courses per treatment arm are listed in Table 2 . Doses were escalated in 36% of patients on the EDX arm and in 45% of patients on the MTX arm. These figures did not change after the dose of EDX had been reduced to 70 mg/m2. The mean maximum dose of EDX given before reduction was 85 mg/m2 (range, 60 to 105) and after dose reduction was 75 mg/m2 (range, 64 to 93). The mean maximum dose of MTX was 45 mg/m2 (range, 38 to 73) throughout the study.
Toxicity
Data on toxicity are available for 256 patients (97%). There were five treatment-related deaths: four on EDX and one on MTX. Three patients treated with EDX died of sepsis during grade 4 granulocytopenia. One of these patients had an unexpected increase in serum creatinine level, which was considered to be the cause of grade 4 leukopenia. In one other case, the grade 4 toxicity of EDX was clearly related to a major protocol violation. One patient on MTX died of cerebral hemorrhage during grade 4 thrombocytopenia. One patient died 3 days after the first injection of EDX and on autopsy was found to have bilateral pneumonia. Review of the case history of this patient showed that it was most likely that he was already suffering from pneumonia when EDX was started.
In general, hematologic toxicity was acceptable and rapidly reversible. Details of hematologic toxicity are listed in Table 3 , Before the dose modification of EDX, 20% of patients experienced grade 3 to 4 granulocyto penia and 8% grade 3 to 4 thrombocytopenia. After dose modification, these figures were 15% and 4%, respec tively, Interestingly, after dose reduction of EDX, a simi lar decrease in hematologic toxicity was observed in both treatment arms. Nonhematologic toxicity and other side effects were comparable in the two periods. However, treatment-related deaths, were only observed before dose reduction, except for the patient with a protocol violation.
Nonhematologic toxicity consisted mainly of stomati tis, gastrointestinal toxicity such as nausea, vomiting, and diarrhea, and skin toxicity. Toxicity details are listed in Table 4 . In general, the pattern of toxicity was similar in both arms, but stomatitis and skin toxicity were more pronounced for EDX than for MTX. Particularly, skin toxicity was significantly more frequent after EDX than after MTX (P < .0015).
Three cardiac events have been reported, two in the EDX-treated group and one in the MTX-treated group. One of these was a grade 4 event on the EDX arm, and refers to circulatory shock in a patient who died of sepsis in grade 4 granulocytopenia. The two other events were reversible minor reductions in blood pressure. Six pulmonary events were observed on the EDX arm and four on the MTX arm. Two patients treated with EDX developed septic shock during grade 4 neutropenia and died of adult respiratory distress syndrome. For both patients, grade 4 pulmonary toxicity was scored. Four other patients experienced grade 1 pulmonary toxicity following EDX treatment, which was reversible in all cases and was not observed again on rechallenge with EDX. In none of these cases was a dose reduction necessary, and no delay or medi cal treatment was required. In three patients on the MTX arm, grade 3 pulmonary toxicity was recorded, which ap peared to be bronchial infection. One other patient had re versible grade 2 pulmonary toxicity that did not require any delays or medication. Subsequent treatment with a 10% reduced dose was uneventful.
Reversible elevations in liver transaminases were ob served on both arms.
Response and Survival
All eligible patients were included in the analyses of response and survival. Twenty-two patients (8.3%) were not assessable for response for various reasons, which included insufficient number of courses (equal for both arms), loss to follow-up evaluation, inability to assess properly response, and lack of data. Response data are listed in Table 5 . There were six CRs and 21 PRs on the EDX arm and nine CRs and 12 PRs on the MTX arm. Thus, the overall response rate (CRs plus PRs) was 21% (95% confidence interval [Cl], 14% to 28%) for EDX and 16% for MTX (95% Cl, 10% to 22%) (P = .392). If patients with an unknown response and nonassessable patients are excluded, the response rates are 23% (95% Cl, 15% to 30%) and 17% (95% Cl, 10% to 24%) for the EDX and MTX arms, respectively (P = .350). The median response duration was 6.1 (months) for EDX and 6.4 months for MTX (log-rank P = .262).
The majority of responses were seen in patients with locoregional disease (35 of 164, 21%; 95% Cl, 16% to 28%) as opposed to metastatic disease (13 of 100, 13%; 95% Cl, 8% to 21%), and although the difference is not statistically significant, there is a trend in favor of locoregional disease. In patients with hypopharynx can cer, significantly fewer responses (P = 0.026, x~ test) were observed than in patients with tumors that originated from the larynx, oral cavity, or oropharynx. Using the multivariate logistic regression model, no other variables were found to be statistically significant.
A multivariate analysis based on the Cox proportional hazards regression model was performed to test for treat ment effect when adjusted for the parameters extent of disease, primary tumor site, sex, and Karnofsky index, and to assess their relative importance with respect to survival. The treatment effect was not statistically sig nificant when these variables were taken into account. Only extent of disease was significantly related to sur vival; patients with metastatic disease had a relative risk of 1.4 (95% Cl, 1.0 to 2.0; P = .006) when compared with patients with locoregional disease.
There was no significant difference in overall or pro gression-free survival (Fig 1) .
DISCUSSION
This randomized phase III study confirmed that EDX is an active drug in the treatment of patients with meta static or recurrent SCC, but demonstrated that there is no difference between EDX and MTX in terms of response 69  53  24  18  77  58  39  29  11  8  Nausea/vomiting  68  52  57  44  4  3  72  54  51  38  4  3   Liver, transaminases  95  73  26  20  8  6  104  78  16  12  7  5   Cutaneous  92  70  28  21  9  7  121  91  5  4  1  1   Diarrhea  113  86  15  11  1  1  111  83  16  12  Infection  113  86  13  10  3  2  116  87 drugs such as MTX and structural analogs. An interesting observation was that following the dose reduction of only EDX, the hematologic toxicity of both EDX and MTX improved. There is no apparent explanation for this, since the dose of MTX was the same throughout the study. A possible explanation could be increased investigator awareness of the risks of both drugs. The general pattern of toxicity of EDX is similar to that of MTX, but EDX was associated with more mucositis and significantly more skin toxicity. Somewhat unexpected was the high incidence (28%) of a characteristic form of skin toxicity of EDX, This consisted of painless, occasionally pruritic, skin lesions not associated with other systemic symptoms such as allergic reactions. The skin lesions were progres sive on continuation of EDX, but resolved completely when the drug was discontinued or with small doses of prednisone. Histologically, it appeared to be a toxic der matitis. The skin toxicity, which is distinct from the rash commonly associated with MTX, has been described in detail elsewhere.18 The dose-limiting toxicity of EDX ap pears to be stomatitis, which was observed in 71% of patients. MTX has been reported to produce response rates of 20% to 40% in this category of patients, depending on the schedule used.1,2,17,19 A weekly dose of 40 to 50 mg/m2 of MTX is considered standard therapy and has been found to be as active as high-dose methotrex ate.2,17 The response rate of 16% in 133 patients treated with M TX is rather disappointing in comparison to the (months) Fig 1. Survival duration of pa  tients treated with EDX (---------) or MTX (-----); lag-rank P -.50. Curves for progression-free sur vival (not shown) were also iden tical for both groups. In the Southwestern Oncology Group study,20 the sur vival of the patients was identical among the three groups, regardless of treatment arm, even though combination chemotherapy with cisplatin and 5-FU had a significantly higher response rate. As in our study, the median survival duration of all patients was approximately 6 months. Vir tually the same survival data were obtained in a previous EORTC study, in which cisplatin was compared with two cisplatin-containing combination regimens. Although the combination regimens had significantly higher response rates than single-agent cisplatin, the overall survival curves were superimp os able, with a median survival time of approximately 6 months. 3 Similar results have been reported from a large trial (249 patients) comparing cis platin plus 5-FU with cisplatin alone and 5-FU alone.21
Number of patients at risk
Although the response rate to the combination (32%) was superior to that achieved with single agents, survival was not improved. Cisplatin and 5-FU had response rates of 17% and 13%, respectively, and thus appeared to have the same level of activity as MTX. However, the conve nience and low cost of weekly administration of MTX in combination with its relatively low level of toxicity make the latter drug more attractive than the former two com pounds. These data indicate that combination chemother" apy should not be standard palliative treatment for pa tients with SCC and that further studies on the quality of palliation are needed.
In addition to the activity in head and neck cancer, EDX is reported to have single-agent activity in nonsmall-cel] lung cancer7,8 and breast cancer.9 A similar pattern of toxicity was observed in those studies com pared with the current study.
In conclusion, the activity of EDX in the treatment of patients with metastatic or recurrent SCC was confirmed in this study. However, in view of the fact that EDX was not more active against SCC than MTX, but had more side effects than the latter drug, EDX cannot be recom mended for routine palliative treatment of patients with SCC. This study, as well as the SWOG study, suggests that the activity of MTX in patients with SCC is less than is stated in the literature. New drugs or approaches that can improve the survival of this group of patients with acceptable toxicity are urgently needed.
